Literature DB >> 23038275

SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells.

Jenna D Lovaas1, Lijia Zhu, Christine Y Chiao, Vanessa Byles, Douglas V Faller, Yan Dai.   

Abstract

BACKGROUND: Matrix metalloproteinase-2 (MMP2) has been shown to play an important role in cancer cell invasion and the expression of MMP2 is associated with the poor prognosis of prostate cancer; however, the mechanism of MMP2 expression is largely unknown. SIRT1 is a nicotinamide adenine dinucleotide-dependent histone deacetylase (class III HDAC) that has recently been shown to have implications in regulating cancer cell growth and apoptosis. The purpose of this study is to determine the role of SIRT1 in regulating MMP2 expression and tumor invasion in prostate cancer cells.
METHODS: The interfering RNAi was used to knockdown SIRT1 from prostate cancer cells. Immunoblots, RT-PCR, zymographic assays, co-immunoprecipitation, analysis and transwell assays were used to examine the effects of SIRT1 silencing on MMP2 expression and activity, on SIRT1 and MMP2 interaction, and on prostate cancer cell invasion. The immuno-histochemical assay was performed to study SIRT1 expression in prostate cancer tissues.
RESULTS: We show that SIRT1 associates and deacetylates MMP2 and SIRT1 regulates MMP2 expression by controlling MMP2 protein stability through the proteosomal pathway. Thus, we demonstrated a novel mechanism in that MMP2 expression can be regulated at the posttranslational level by SIRT1. Furthermore, we determined that SIRT1 inhibition reduced prostate cancer cell invasion and SIRT1 is highly expressed in advanced prostate cancer tissues.
CONCLUSIONS: SIRT1 is an important regulator of MMP2 expression, activity, and prostate cancer cell invasion. Overexpressed SIRT1 in advanced prostate cancer may play an important role in prostate cancer progression.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23038275      PMCID: PMC3839321          DOI: 10.1002/pros.22592

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  31 in total

1.  Clinical states in prostate cancer: toward a dynamic model of disease progression.

Authors:  H I Scher; G Heller
Journal:  Urology       Date:  2000-03       Impact factor: 2.649

2.  Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor-associated endothelial cells.

Authors:  J Erik Busby; Sun-Jin Kim; Sertac Yazici; Toru Nakamura; Jang-Seong Kim; Junqin He; Marva Maya; Xuemei Wang; Kim-Anh Do; Dominic Fan; Isaiah J Fidler
Journal:  Prostate       Date:  2006-12-01       Impact factor: 4.104

3.  SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis.

Authors:  V Byles; L Zhu; J D Lovaas; L K Chmilewski; J Wang; D V Faller; Y Dai
Journal:  Oncogene       Date:  2012-01-16       Impact factor: 9.867

Review 4.  Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Carcinogenesis       Date:  2005-09-29       Impact factor: 4.944

5.  Function of the SIRT1 protein deacetylase in cancer.

Authors:  Walter Stünkel; Bee Keow Peh; Yong Cheng Tan; Vasantha M Nayagam; Xukun Wang; Manuel Salto-Tellez; BinHui Ni; Michael Entzeroth; Jeanette Wood
Journal:  Biotechnol J       Date:  2007-11       Impact factor: 4.677

6.  Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients.

Authors:  Ruo-Chia Tseng; Chin-Chu Lee; Han-Shui Hsu; Ching Tzao; Yi-Ching Wang
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

7.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

8.  The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation.

Authors:  Jiandi Zhang
Journal:  J Biol Chem       Date:  2007-09-27       Impact factor: 5.157

9.  SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.

Authors:  Kyu Yun Jang; Sung Ho Hwang; Keun Sang Kwon; Kyung Ryoul Kim; Ha Na Choi; Na-Ri Lee; Jae-Yong Kwak; Byung-Hyun Park; Ho Sung Park; Myoung Ja Chung; Myoung Jae Kang; Dong Geun Lee; Hun Soo Kim; Hyeok Shim; Woo Sung Moon
Journal:  Am J Surg Pathol       Date:  2008-10       Impact factor: 6.394

10.  SIRT1 is significantly elevated in mouse and human prostate cancer.

Authors:  Derek M Huffman; William E Grizzle; Marcas M Bamman; Jeong-su Kim; Isam A Eltoum; Ada Elgavish; Tim R Nagy
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

View more
  31 in total

1.  SIRT1 is a Highly Networked Protein That Mediates the Adaptation to Chronic Physiological Stress.

Authors:  Michael W McBurney; Katherine V Clark-Knowles; Annabelle Z Caron; Douglas A Gray
Journal:  Genes Cancer       Date:  2013-03

2.  SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.

Authors:  Min-Sun Jin; Chang Lim Hyun; In Ae Park; Ji Young Kim; Yul Ri Chung; Seock-Ah Im; Kyung-Hun Lee; Hyeong-Gon Moon; Han Suk Ryu
Journal:  Tumour Biol       Date:  2015-10-30

3.  SIRT1 inactivation evokes antitumor activities in NSCLC through the tumor suppressor p27.

Authors:  Lijia Zhu; Christine Y Chiao; Katelyn G Enzer; Alexander J Stankiewicz; Douglas V Faller; Yan Dai
Journal:  Mol Cancer Res       Date:  2014-08-20       Impact factor: 5.852

4.  Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc.

Authors:  Y Liu; X Li; S Zhu; J-g Zhang; M Yang; Q Qin; S-c Deng; B Wang; K Tian; L Liu; Y Niu; C-y Wang; G Zhao
Journal:  Gene Ther       Date:  2015-04-28       Impact factor: 5.250

5.  Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria.

Authors:  Gabriele Di Sante; Timothy G Pestell; Mathew C Casimiro; Sara Bisetto; Michael J Powell; Michael P Lisanti; Carlos Cordon-Cardo; Mireia Castillo-Martin; Dennis M Bonal; Valentina Debattisti; Ke Chen; Liping Wang; Xiaohong He; Michael W McBurney; Richard G Pestell
Journal:  Am J Pathol       Date:  2015-01       Impact factor: 4.307

6.  Association between MMP-2 expression and prostate cancer: A meta-analysis.

Authors:  Tiancheng Xie; Binbin Dong; Yangye Yan; Guanghui Hu; Yunfei Xu
Journal:  Biomed Rep       Date:  2015-12-08

Review 7.  Carcinoma of the gastroesophageal junction in Chinese patients.

Authors:  Qin Huang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

8.  SIRT1 controls cell proliferation by regulating contact inhibition.

Authors:  Elizabeth H Cho; Yan Dai
Journal:  Biochem Biophys Res Commun       Date:  2016-08-08       Impact factor: 3.575

Review 9.  Post-Translational Modifications That Drive Prostate Cancer Progression.

Authors:  Ivana Samaržija
Journal:  Biomolecules       Date:  2021-02-09

10.  GREM2 maintains stem cell-like phenotypes in gastric cancer cells by regulating the JNK signaling pathway.

Authors:  Ao Ran; Lin Guan; Jiani Wang; Ying Wang
Journal:  Cell Cycle       Date:  2019-08-25       Impact factor: 5.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.